Bristol-Myers Squibb News

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

05.12.07	Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community (PR Newswire)
30.11.07	Bristol-Myers Squibb, New Jersey Children's Hospital Launch Center for Immune System Disorders & Infectious Diseases Including HIV/AIDS (PR Newswire)
14.11.07	New England Journal of Medicine Study Shows ERBITUX(R) Improves Survival in Advanced Colorectal Cancer (PR Newswire)
12.11.07	Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept) (PR Newswire)
09.11.07	FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML (PR Newswire)
25.10.07	Bristol-Myers Squibb Company Reports Financial Results for the Third Quarter and First Nine Months of 2007 (PR Newswire)
18.10.07	European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) (PR Newswire)
17.10.07	Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV (PR Newswire)
17.10.07	Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV (Businesswire)
03.10.07	Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports Use as a Single Agent in Patients with Advanced Colorectal Cancer (Businesswire)
11.09.07	ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study (PR Newswire)
27.08.07	Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program (PR Newswire)
26.07.07	Bristol-Myers Squibb Company Reports Financial Results for the Second Quarter and First Half of 2007 (PR Newswire)
17.07.07	ABILIFY(R) (aripiprazole) Supplemental New Drug Application Receives Priority Review by U.S. Food And Drug Administration for Adjunctive Treatment in Adults With Major Depressive Disorder (PR Newswire)
21.05.07	Six-Week Investigational Study In Adults With Major Depressive Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole Therapy With Antidepressants (PR Newswire)
21.05.07	BARACLUDE(R) (Entecavir) Treatment Demonstrated Greater Viral Load Reduction Compared to Adefovir at 48 Weeks in Study of Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients (PR Newswire)
26.04.07	Bristol-Myers Squibb and Pfizer Announce Worldwide Collaboration to Develop and Commercialize Anticoagulant and Metabolic Compounds (PR Newswire)
23.04.07	Crohn's Patient Robert Hill Summits Carstensz Pyramid, Sixth in Seven Summits Campaign (PR Newswire)
13.04.07	BARACLUDE(R) (entecavir) Therapy Resulted in Undetectable Levels of Hepatitis B Virus in Cohort of Patients Who Re-Started Treatment (PR Newswire)
25.01.07	Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2006 and Announces EPS Guidance for 2007 (PR Newswire)
11.01.07	Bristol-Myers Squibb and AstraZeneca Announce Worldwide Collaboration to Develop and Commercialize Diabetes Compounds (PR Newswire)
12.12.06	ABILIFY(R) (Aripiprazole) Injection for Intramuscular Use for Adults With Agitation Associated With Schizophrenia or Bipolar Mania Now Available (PR Newswire)
20.11.06	Crohn's and Colitis Foundation of America and ConvaTec Recognize Young Patients With Inflammatory Bowel Disease (PR Newswire)
13.11.06	ORENCIA(R) (abatacept) Data Demonstrated Improvement in Children and Adolescents With Juvenile Idiopathic Arthritis as Measured by the Validated ACR Pediatric Criteria (PR Newswire)
05.10.06	Accenture and Edge Dynamics Launch Next Phase of Channel Commerce Management Initiative for Bristol-Myers Squibb (PR Newswire)
28.09.06	Crohn's & Colitis Foundation of America and ConvaTec Announce 2006 Great Comebacks Regional Awards Recipients (PR Newswire)
12.09.06	Bristol-Myers Squibb Board of Directors Announces Departure of Peter R. Dolan as CEO and Appointment of James M. Cornelius as Interim CEO (PR Newswire)
16.08.06	Program Leaders Outline Effective Strategies for Fighting HIV/AIDS in Children in Resource-Limited Settings (PR Newswire)
16.08.06	Program Leaders Outline Effective Strategies for Fighting HIV/AIDS in Children in Resource-Limited Settings (PR Newswire)
27.07.06	Bristol-Myers Squibb Company Reports Financial Results for the Second Quarter and First Half of 2006 (PR Newswire)
28.06.06	FDA Approves SPRYCEL(TM) (dasatinib) With Two Indications (PR Newswire)
23.05.06	96-Week Viral Suppression Data From Two Studies Presented for BARACLUDE(R) (entecavir) in Chronically-Infected Hepatitis B Patients (PR Newswire)
02.03.06	FDA Approves ERBITUX(R) (Cetuximab) for Treatment of Head and Neck Cancer; First and Only Approved Monoclonal Antibody for Squamous Cell Carcinoma of the Head and Neck (Businesswire)
28.02.06	U.S. Food and Drug Administration Approves EMSAM(R) (selegiline transdermal system), the First Transdermal Patch for the Treatment of Major Depressive Disorder (PR Newswire)
24.02.06	Eröffnung des ersten medizinischen Zentrums für an HIV/AIDS erkrankte Kinder in Swasiland; Aufbau von Behandlungskapazitäten in dem am härtesten getroffenen Land der Welt (PR Newswire)
24.02.06	Swaziland's First Children's HIV/AIDS Medical Center Opens; Building Treatment Capacity in the World's Hardest Hit Country (PR Newswire)
25.01.06	Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2005 and Announces EPS Guidance for 2006 (PR Newswire)
23.01.06	Crohn's Patient Robert Hill Reaches Peak of Antarctica's Tallest Mountain (PR Newswire)
18.01.06	FDA Grants Priority Review to PLAVIX(R) (Clopidogrel Bisulfate) Supplemental New Drug Application (sNDA) for Additional Type of Heart Attack (PR Newswire)
09.01.06	Bristol-Myers Squibb and Gilead Announce Data Supporting Bioequivalence for Single-Pill Fixed-Dose Regimen of Sustiva(R) (efavirenz) and Truvada(R) (emtricitabine and tenofovir disoproxil fumarate) (Businesswire)
13.12.05	PLAVIX(R) (clopidogrel bisulfate) Recommended as Effective Cardiovascular Risk Reduction Treatment for Patients With Established Peripheral Arterial Disease (P.A.D.) (PR Newswire)
05.12.05	Domantis Announces Therapeutic Alliance with Bristol-Myers Squibb (PR Newswire)
14.11.05	BARACLUDE(TM) (entecavir) Two-year Data Analysis Did Not Detect Emergence of Resistance in Nucleoside-Naive Chronic Hepatitis B Patients (PR Newswire)
31.10.05	Merck und Bristol-Myers Squibb lizenzieren neue AIDS-Medikamente an IPM zur Entwicklung von Mikrobiziden zum Schutz von Frauen vor HIV (PR Newswire)
28.10.05	Bristol-Myers Squibb Company Reports Financial Results for the Third Quarter and First Nine Months of 2005, Reflecting Ongoing Investments in Strategy Aimed at Delivering Sustainable Growth (PR Newswire)
19.09.05	Walgreens Acquires the Rights to Theragran-M Multivitamins (PR Newswire)
09.09.05	Bristol-Myers Squibb and Merck Joint Statement on FDA Advisory Committee Vote on PARGLUVA(TM) (Muraglitazar), an Investigational Oral Treatment for Type 2 Diabetes (PR Newswire)
06.09.05	Bristol-Myers Squibb Statement on FDA Advisory Committee Vote on ORENCIA(R) (Abatacept), an Investigational Selective Modulator of T-Cell Co-Stimulation for Rheumatoid Arthritis (PR Newswire)
20.05.05	New Study Shows Investigational Compound Muraglitazar Significantly Lowered Blood Glucose Levels As Measured By A1C Reduction in Patients With Type 2 Diabetes (PR Newswire)
28.04.05	Elixir Pharmaceuticals Licenses Novel Growth Hormone Secretagogue Comp (Businesswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

22.11.24		Dow Jones aktuell: Dow Jones zum Ende des Freitagshandels in der Gewinnzone
22.11.24		SIX-Handel: SLI zeigt sich zum Ende des Freitagshandels fester
22.11.24		Pluszeichen in Zürich: SMI zum Ende des Freitagshandels mit grünem Vorzeichen
22.11.24		Gute Stimmung in Europa: Anleger lassen STOXX 50 letztendlich steigen
22.11.24		Deutsche Bank AG: Novartis-Aktie erhält Hold
22.11.24		Freitagshandel in New York: Dow Jones zum Start des Freitagshandels fester
22.11.24		Optimismus in Europa: So entwickelt sich der Euro STOXX 50 am Freitagnachmittag
22.11.24		Pluszeichen in Europa: STOXX 50 notiert im Plus